American Journal of Cardiology
Volume 102, Issue 12 , Pages 1698-1705, 15 December 2008

Relation of Systolic Blood Pressure to Survival in Both Ischemic and Nonischemic Systolic Heart Failure

  • Richard K. Cheng, MD

      Affiliations

    • Department of Medicine, UCLA Medical Center, Los Angeles, California
  • ,
  • Tamara B. Horwich, MD, MS

      Affiliations

    • Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California
  • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California
    • Corresponding Author InformationCorresponding author: Tel: 310-206-9112; fax: 310-206-9111

Received 26 May 2008; received in revised form 30 July 2008; accepted 30 July 2008. published online 22 September 2008.

High systolic blood pressure (SBP) is a predictor of survival for patients with heart failure (HF). Whether SBP predicts survival in both ischemic and nonischemic HF has not been well examined. We analyzed 2,178 patients with advanced HF (47.3% ischemic etiology, 75.5% men, 93.5% New York Heart Association class III or IV, age 52 ± 13, left ventricular ejection fraction 24 ± 9%) referred to a university center between 1983 and 2006. SBP and invasive hemodynamic variables were recorded after optimization of medical therapy. Patients were divided into SBP quartiles (≤90, 91 to 100, 101 to 112, ≥113 mm Hg) based on SBP frequency. Survival free from death or urgent transplant in ischemic versus nonischemic HF was 53.2% versus 61.1% at 2 years. Higher SBP quartile was associated with increased survival in the total cohort and in subgroups of both nonischemic and ischemic HF. On multivariate analysis adjusting for age, left ventricular ejection fraction, cholesterol, gender, diabetes mellitus, pulmonary capillary wedge pressure, cardiac index, New York Heart Assocation class, β-blocker use, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, statin use, and smoking history, relative risk (95% confidence interval) of death or urgent transplant at 2 years for quartile 1 compared with quartile 4 was 1.9 (1.4 to 2.6) in the total cohort, 1.6 (1.1 to 2.5) in nonischemic HF, and 2.4 (1.5 to 3.7) in ischemic HF. In conclusion, SBP predicts HF survival in both ischemic and nonischemic HF independent of other risk factors and invasive hemodynamic variables.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This research was supported in part by the Ahmanson Foundation, Los Angeles, California. Dr. Horwich was supported by National Heart, Lung, and Blood Institute, Bethesda, Maryland, grant 1K23HL085097. Dr. Fonarow holds the Eliot Corday Chair in Cardiovascular Medicine and Science.

PII: S0002-9149(08)01395-7

doi:10.1016/j.amjcard.2008.07.058

American Journal of Cardiology
Volume 102, Issue 12 , Pages 1698-1705, 15 December 2008